ClinicalTrials.gg
CompletedNCT06713265Freez in parkUpdated Oct 30, 2026

Study of the Link Between Freezing of Gait and Oropharyngeal Freezing in Parkinson's Patients

An observational study in Parkinson's Disease, Dysphagia and Swallowing Disorder, sponsored by Hopital La Musse. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Hopital La Musse · Observational

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
33
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 428 studies in Parkinson Disease with a site in France — 63 open to participants now, 76 under way, 4 of them phase 3. Parkinson Disease · France.

Enrollment
78th of 98
33 · median 90
Started
2024
with 14 others
Observational
99 of 428
22 open now
Registered
399th of 428
by date

Among the 428 studies in Parkinson Disease with a site in France, this one is the 78th largest by enrollment of the 98 observational ones that give a count, is one of 15 that started in 2024, is one of 99 observational ones, and was the 399th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

63 of the 428 studies in Parkinson Disease with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 428 studies in Parkinson Disease with a site in France, or all of them as a file.
02

Study summary

Parkinson's Disease: Study of the Link Between Gait Freezing and Oropharyngeal Freezing Parkinson's disease is the second most common neurodegenerative disorder worldwide. Parkinsonian dysphagia is a frequently encountered disorder in this condition, affecting all phases of swallowing: oral, pharyngeal, and esophageal. This dysphagia can occur at any stage of the disease. While most swallowing difficulties develop in the advanced stages of Parkinson's disease, they can also appear early on and are often underdiagnosed. The prevalence of swallowing disorders in Parkinson's disease is estimated to range from 40% to 80%, with this variability explained by the significant differences in the precision of swallowing evaluations conducted and the fact that dysphagia is still too frequently underdiagnosed. Yet, dysphagia is the leading cause of mortality in Parkinson's patients.

Dysphagia can negatively affect patients' quality of life. It leads to difficulties during oral intake (food, liquids, and medications), weight loss, dehydration, malnutrition, and limitations in social activities. Depression is frequently associated with reduced quality of life in Parkinson's patients with swallowing disorders. Moreover, aspiration pneumonia due to mis-swallowing is one of the primary reasons for hospitalization in Parkinson's patients, potentially leading to severe complications and, at times, death.

Oropharyngeal freezing, also called oral festination, is an involuntary, repetitive anteroposterior movement of the tongue against the soft palate performed before transferring the food bolus to the pharynx. This movement is also observed during multiple swallows. This phenomenon is more frequent in dysphagic Parkinson's patients, yet its impact on swallowing dynamics remains poorly understood. Oropharyngeal freezing has been observed in approximately 40% to 75% of Parkinson's patients during videofluoroscopic swallow studies, also known as swallowing pharyngography. Oropharyngeal freezing inhibits the initiation of swallowing, keeping the airway open and leading to tracheal aspiration of residues. Some fragments then slide into the valleculae and pyriform sinuses. Thus, oropharyngeal freezing exacerbates pharyngeal phase incoordination, increasing the risk of aspiration pneumonia. Therefore, addressing this swallowing disorder is essential.

Oropharyngeal freezing is intrinsically rhythmic. While limited studies have been conducted on the topic, they agree that gait freezing (difficulty initiating walking, stopping in response to obstacles, or circumventing them) and oropharyngeal freezing share common pathophysiological mechanisms. Gait freezing is not limited to deficits in the locomotor network but is part of a broader deficit affecting spatiotemporal coordination in various tasks, similar to oropharyngeal freezing.

It is, therefore, crucial to detect this oral phase swallowing disorder as early as possible, enabling tailored early intervention that helps patients maintain their swallowing abilities for as long as possible and prevents complications mentioned earlier. Since gait freezing is diagnosed much earlier and more systematically, it would be interesting to investigate whether there is a correlation between the presence of gait freezing and oropharyngeal freezing in these patients. This could guide patients with gait freezing toward early speech-language assessments to evaluate the presence of oropharyngeal freezing.

The objectives of the study are examine the prevalence of oropharyngeal freezing in Parkinson's patients. Based on the results obtained from the NFOG-Q (New Freezing of Gait Questionnaire), two groups will be formed: The first group will consist of patients exhibiting gait freezing. The second group will consist of patients without gait freezing. The secondary objectives of the study are examine the common characteristics between these two types of freezing (gait and oropharyngeal). To assess the sensitivity and reliability of the NFOG-Q in detecting oropharyngeal freezing.To determine the prevalence of oropharyngeal freezing based on the score obtained on the UPDRS (Unified Parkinson's Disease Rating Scale). To analyze the link between patients' rhythmic abilities and the presence or absence of one or both types of freezing.

03

Conditions studied

  • Parkinson's Disease
  • Dysphagia
  • Swallowing Disorder
  • Freezing of Gait
  • Oropharyngeal Disease
  • Gait Disorders

Keywords

  • Parkinson's Disease
  • Dysphagia
  • Swallowing disorder
  • Freezing of gait
  • oropharyngeal freezing
  • Gait
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The chosen study population consists of patients with idiopathic Parkinson's disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of idiopathic Parkinson's disease established by a neurologist;
  • Patient affiliated with the social security system;
  • Patient aged over 18 years.

Exclusion criteria

Exclusion Criteria:

  • Patients under legal protection measures;
  • Neurological history that could be the cause of a swallowing disorder (e.g., stroke) or a history of ENT cancer;
  • Patient with a gastrostomy without oral intake;
  • Pregnant women or those suspected of being pregnant;
  • Minor patients
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
33 participants (actual)
Patient registry
No

Groups and cohorts

  • With freezing of gait

    During patient enrollment, the following assessments will be conducted: * The Unified Parkinson's Disease Rating Scale (UPDRS); * Timed Up \& Go (TUG) Test; * New Freezing of Gait Questionnaire (NFOG-Q); * BAASTA Battery; * Clinical swallowing assessment. All assessments will be conducted during the patient's OFF phase. At the end of the motor assessment (NFOG-Q and TUG), the patients will be divided into two groups: the first group will consist of patients exhibiting freezing of gait, while the second group will consist of those not presenting freezing. The procedure for the assessments will remain the same for both groups. If, during the clinical speech therapy swallowing assessment, signs indicative of swallowing disorders are detected, the patient will be referred for a pharyngography to specify the nature of these disorders.

  • Without freezing of gait

    During patient enrollment, the following assessments will be conducted: * The Unified Parkinson's Disease Rating Scale (UPDRS); * Timed Up \& Go (TUG) Test; * New Freezing of Gait Questionnaire (NFOG-Q); * BAASTA Battery; * Clinical swallowing assessment. All assessments will be conducted during the patient's OFF phase. At the end of the motor assessment (NFOG-Q and TUG), the patients will be divided into two groups: the first group will consist of patients exhibiting freezing of gait, while the second group will consist of those not presenting freezing. The procedure for the assessments will remain the same for both groups. If, during the clinical speech therapy swallowing assessment, signs indicative of swallowing disorders are detected, the patient will be referred for a pharyngography to specify the nature of these disorders.

06

What researchers measure

Primary outcomes

  1. The judgment of the presence or absence of oropharyngeal freezing during a pharyngography in the OFF phase of an idiopathic Parkinson's disease patient.

    Pharyngography is a swallowing examination that allows for recording films of the patient's swallowing using a radiological device. The radiology device will be positioned at the patient's neck and will record these sequences. Once the device is in place, the patient will swallow bites of varying thickness. For all swallowing actions, barium will be used, which is a radiopaque, white substance with a slightly mentholated taste.

    Time frame: At the enrollement

Secondary outcomes

  1. The objective assessment of the severity, fluctuation, and progression of clinical symptoms, as well as their impact on the patient's daily life.

    The Unified Parkinson's Disease Rating Scale (UPDRS) is a composite measurement tool that combines several evaluation scales and is organized into six sections. It is a multidimensional scale that allows for an objective assessment of the severity, fluctuations, and progression of clinical symptoms, as well as their impact on the patient's daily life. The first section evaluates the patient's mental, behavioral, and mood state. The second section allows for a self-assessment of activities of daily living. The third section assesses motor functions, while the fourth section evaluates treatment complications over the week prior to the examination. The fifth section involves the administration of the Hoehn and Yahr scale, which classifies patients into five main stages based on the severity of their condition. The final section is the Schwab and England quality of life scale, which evaluates the patient's ability to perform activities of daily living in terms of speed and autonomy.

    Time frame: At the enrollement

  2. Assessment of gait freezing

    The New Freezing of Gait Questionnaire (NFOG-Q) is a 9-item questionnaire excluding patients with no freezing in item 1, duration and frequency of freezing in items 2 to 6, and the impact of freezing on daily activities in items 7 to 9). The concurrent validity is poor when compared to the freezing time in a TUG test and the number of freezing events that occurred. The reliability and internal consistency are good. Video assistance may improve scoring.

    Time frame: At the enrollement

  3. Assessment of gait freezing 2

    The Timed Up and Go (TUG) test is a simple test conducted during a consultation: the subject, seated on a chair, must stand, walk 3 meters, turn around, and return to sit. The score is given by the time in seconds. The test is normal if the time is less than 14 seconds (or 20 seconds according to some publications). The TUG test has good reproducibility over time and between observers. Its sensitivity is 87%, and its specificity is 87%.

    Time frame: At the enrollement

  4. Rhythm assessment

    The BAASTA Battery is a series of tests on a touchscreen tablet that assess rhythmic perceptual and sensorimotor abilities. It is used to detect deficits in rhythmic abilities through patented measurement methods and is designed for researchers and healthcare providers to assess the motor synchronization of their subjects/patients. They perform a series of exercises to evaluate their rhythmic abilities, such as tapping in time with sounds, music, and detecting isochrony errors.

    Time frame: At the enrollement

  5. Assessment of swallowing disorders

    The Modified Barium Swallow Impairment Profile (MBSImP) is a standardized protocol for pharyngography to interpret and communicate swallowing disorders in a specific, consistent, precise, and objective manner.

    Time frame: At the enrollement

  6. Assessing functional swallowing ability over time

    The Functional Oral Intake Scale (FOIS) is a scale used to document any changes in a patient's diet, reflecting the evolution of their functional swallowing abilities over time. Level 1 corresponds to "nothing by mouth," and level 7 corresponds to a "complete oral diet without restriction." This scale will be used during the clinical speech therapy assessment.

    Time frame: At the enrollement

  7. Assessming of the severity of aspiration events

    The Penetration Aspiration Scale (PAS) evaluates the severity of aspiration events. It is an 8-point scale, where score 1 indicates normal swallowing, and score 8 represents the most severe level, corresponding to silent aspiration. This scale will be used during nasofibroscopy and pharyngography exams.

    Time frame: At the enrollement

  8. Quantitative assessment of the effectiveness of solid food ingestion

    The Test of Masticating and Swallowing Solids (TOMASS) allows for a quantitative assessment of the effectiveness of solid food ingestion. The patient is asked to eat a Tuc cracker as quickly and comfortably as possible and to state their name after the last swallow. The goal is to quantitatively evaluate the chewing and swallowing of a solid bolus. The examiner records the number of bites, chewing cycles, swallows, and total time. Norms are established based on age and gender, as these are considered influential factors on chewing. This test will be conducted during the clinical speech therapy assessment.

    Time frame: At the enrollement

  9. Quantitative evaluation of the effectiveness of liquid bolus ingestion

    The Waster Swallowing Test (TWST) provides a quantitative evaluation of the effectiveness of liquid bolus ingestion. The patient is asked to drink a glass of water (150 mL for patients under 75 years old, and 100 mL for those over 75 years old) as quickly and comfortably as possible. The goal is to quantitatively evaluate liquid swallowing. The number of swallows and the total ingestion time are recorded. This test will be conducted during the clinical speech therapy assessment.

    Time frame: At the enrollement

  10. Detection of clinical signs of dysphagia, including silent aspirations

    The Volume-Viscosity Swallow Test (V-VST) offers a quick, safe, and accurate diagnostic test to detect clinical signs of dysphagia, including silent aspirations. The test is detailed and easy to use, with good sensitivity (88.2%) and specificity (64.7%). The V-VST protocol includes three texture tests in this order: nectar, paste, and liquid. The liquid is colored with either mint or grenadine syrup, based on patient preference, to improve visual and taste appeal. Each texture is tested in three different volumes (5, 10, 20 mL) using both a spoon and a glass, while monitoring oxygen saturation with a fingertip pulse oximeter. Swallowing disorders are divided into two main categories: propulsion disorders and airway protection disorders.

    Time frame: At the enrollement

  11. Assessment of the quality of life of patients with oropharyngeal dysphagia

    The Swallowing Quality of Life (SWAL-QOL) is a 44-item questionnaire that addresses 10 concepts related to the quality of life of patients with oropharyngeal dysphagia. Each concept corresponds to a subscale: the burden of swallowing difficulties, meal duration, desire to eat, food choices, communication, fear, mental health, social impact, fatigue, and sleep. Each item is rated on a 5-point scale, and the total score is calculated, with a maximum score of 100. The lower the score, the worse the quality of life. This test will be conducted during the clinical speech therapy assessment.

    Time frame: At the enrollement

07

Study locations

1 site
  • Hôpital La Musse
    Saint-Sébastien-de-Morsent, 27180, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Dec 2025, 14 months.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's 14 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Oct 2025 → Dec 2025 and completion Nov 2025 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 3, 2024
StartActual
Oct 4, 2024
Primary completionActual
Dec 16, 2025was Oct 2025
CompletionActual
Jun 30, 2026was Nov 2025
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 30, 2026
Sites
1 site added, 1 site removed
Show site
  • Hôpital La Musse · Saint-Sébastien-de-Morsent, France
Show 1 removed
  • Hôpital La Musse · Saint Sébastien de Morsent, France
Oct 30, 2026
Primary completion
Oct 31, 2025→Dec 16, 2025 (actual)
Oct 30, 2026
Study completion
Nov 30, 2025→Jun 30, 2026 (actual)
Oct 30, 2026
Enrollment
66 (estimated)→33 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Hôpital La Musse · Saint-Sébastien-de-Morsent, France
    Show 1 removed
    • Hôpital La Musse · Saint Sébastien de Morsent, France
    Primary completion Oct 31, 2025→Dec 16, 2025 (now actual)
    Study completion Nov 30, 2025→Jun 30, 2026 (now actual)
    Enrollment 66 (estimated)→33 (actual)
    + 4 other changes: verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06713265
Lead sponsor
Hopital La Musse
Responsible party
Sponsor
First posted
Dec 3, 2024
Start date
Oct 4, 2024
Primary completion
Dec 16, 2025
Completion
Jun 30, 2026
Last update
Oct 30, 2026

Study contacts

Héloïse BAILLET, PhD
principal investigator · Hôpital La Musse
Eric VERIN, PU-PH
study director · CHU Rouen, GRHVN Laboratory

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion